The NICE has issued final draft guidance endorsing the use of CSL Vifor's Filspari (sparsentan) for primary IgA nephropathy.

In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...

GSK has received approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab).

Aptar Digital Health has signed a licensing agreement with AstraZeneca for detecting CKD using the latter’s AI-driven ...

Genentech has announced an investment exceeding $700m to establish its first East Coast manufacturing facility in North ...

The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their ...

The Trump administration’s budget reconciliation bill has passed the US House of Representatives by a wafer-thin single-vote ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for ...

Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech for small-molecule monovalent glue medicine ...

Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in the company ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...